Time filter

Source Type

News Article | November 21, 2016
Site: www.prnewswire.co.uk

ReportsnReports.com adds "Tuberculosis - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Tuberculosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Complete report on H2 2016 pipeline review of Tuberculosis with 108 market data tables and 17 figures, spread across 393 pages is available at http://www.reportsnreports.com/reports/755901-tuberculosis-pipeline-review-h2-2016.html. Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. Companies discussed in this Tuberculosis Pipeline Review, H2 2016 report include Abera Bioscience AB, Akthelia Pharmaceuticals Limited, Alvogen Korea Co., Ltd., Anacor Pharmaceuticals, Inc., Archivel Farma S.L., AstraZeneca Plc, Beech Tree Labs, Inc., BioDiem Ltd, BioLingus AG, Biomar Microbial Technologies, Bioversys AG, Celgene Corporation, Cellceutix Corporation, Chongqing Zhifei Biological Products Co., Ltd., Crestone, Inc., Dafra Pharma International Ltd., Daiichi Sankyo Company, Limited, Demuris Limited, Eisai Co., Ltd., Eli Lilly and Company, Ensol Biosciences Inc., EpiVax, Inc., FIT Biotech Oy, GangaGen Inc., GlaxoSmithKline Plc, Globeimmune, Inc., Hager Biosciences, LLC, Hsiri Therapeutics LLC, Imaxio SA, Immunitor, Inc., ImmunoBiology Limited, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Lakewood-Amedex Inc, Lipotek Pty Ltd., Matinas BioPharma Holdings, Inc., Microbion Corporation, Microbiotix, Inc., NEARMEDIC PLUS, Ltd, Novartis AG, NovoBiotic Pharmaceuticals, LLC, Otsuka Holdings Co., Ltd., QureTech Bio AB, Recce Pty Ltd, Rodos BioTarget GmbH, Sanofi, Sanofi Pasteur SA, Sarepta Therapeutics, Inc., Sequella, Inc., Shionogi & Co., Ltd., Sphaera Pharma Pvt. Ltd., Spring Bank Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TetraLogic Pharmaceuticals, TGV-Laboratories, Theravectys SA, Tomegavax, Inc., Transgene SA, TVAX Biomedical, Inc., Univalue Valorizacion, S.L., Vaccibody AS, Vakzine Projekt Management GmbH, Vaxil Bio Therapeutics Ltd. and Vichem Chemie Research Ltd. The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 7, 8, 61, 37 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 4, 5, 35 and 37 molecules, respectively. Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Scope of this report: The report provides a snapshot of the global therapeutic landscape of Tuberculosis and reviews pipeline therapeutics for Tuberculosis by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Tuberculosis therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Tuberculosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Tuberculosis. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on: Facebook: https://www.facebook.com/ReportsnReports/ LinkedIn: https://www.linkedin.com/company/reportsnreports Twitter: https://twitter.com/marketsreports G+ / Google Plus: https://plus.google.com/111656568937629536321/posts RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml


PubMed | University of Cantabria, Interamerican University of Puerto Rico, Biomar Microbial Technologies and University of Puerto Rico at San Juan
Type: Journal Article | Journal: mBio | Year: 2015

Bacterial conjugation constitutes a major horizontal gene transfer mechanism for the dissemination of antibiotic resistance genes among human pathogens. Antibiotic resistance spread could be halted or diminished by molecules that interfere with the conjugation process. In this work, synthetic 2-alkynoic fatty acids were identified as a novel class of conjugation inhibitors. Their chemical properties were investigated by using the prototype 2-hexadecynoic acid and its derivatives. Essential features of effective inhibitors were the carboxylic group, an optimal long aliphatic chain of 16 carbon atoms, and one unsaturation. Chemical modification of these groups led to inactive or less-active derivatives. Conjugation inhibitors were found to act on the donor cell, affecting a wide number of pathogenic bacterial hosts, including Escherichia, Salmonella, Pseudomonas, and Acinetobacter spp. Conjugation inhibitors were active in inhibiting transfer of IncF, IncW, and IncH plasmids, moderately active against IncI, IncL/M, and IncX plasmids, and inactive against IncP and IncN plasmids. Importantly, the use of 2-hexadecynoic acid avoided the spread of a derepressed IncF plasmid into a recipient population, demonstrating the feasibility of abolishing the dissemination of antimicrobial resistances by blocking bacterial conjugation.Diseases caused by multidrug-resistant bacteria are taking an important toll with respect to human morbidity and mortality. The most relevant antibiotic resistance genes come to human pathogens carried by plasmids, mainly using conjugation as a transmission mechanism. Here, we identified and characterized a series of compounds that were active against several plasmid groups of clinical relevance, in a wide variety of bacterial hosts. These inhibitors might be used for fighting antibiotic-resistance dissemination by inhibiting conjugation. Potential inhibitors could be used in specific settings (e.g., farm, fish factory, or even clinical settings) to investigate their effect in the eradication of undesired resistances.


News Article | November 11, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Acne Vulgaris   ,complete with analysis by stage of development,drug target,mechanism of action (MoA),route of administration (RoA) and molecule type. The report also coversthe descriptive pharmacological action of the therapeutics,its complete research and development history and latest news and press releases. Additionally,the report provides an overview of key players involved in therapeutic development for Acne Vulgaris    and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios,enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Acne Vulgaris  - Pipeline Review,H2 2016 addition with 71 market data tables and 17 figures, spread across 200 pages is available at http://www.rnrmarketresearch.com/acne-vulgaris-pipeline-review-h2-2016-market-report.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases,company/university websites,clinical trial registries,conferences,SEC filings,investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally,various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. 3SBio Inc. ,Allergan Plc ,Almirall, S.A. ,Antibiotx ApS ,Biomar Microbial Technologies,BiopharmX, Inc.,Braintree Laboratories, Inc.,Brickell Biotech, Inc.,Cell Medica Limited,Cellceutix Corporation,Celtaxsys, Inc. ,Common Pharma Inc,Cutanea Life Sciences Inc,DermaXon, LLC ,Dermira Inc. Diffusion Pharmaceuticals Inc.,ELORAC, Inc. ,Ensol Biosciences Inc.,Foamix Pharmaceuticals Ltd.,Galderma S.A. ,GlaxoSmithKline Plc,Helix BioMedix, Inc.,Hovione FarmaCiencia SA,Lee's Pharmaceutical Holdings Limited,LEO Pharma A/S,Novabiotics Limited,Novan, Inc. ,Paratek Pharmaceuticals, Inc.,Pfizer Inc. Inquire before buying http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=748010(This is a premium report price at US$2000 for a single user PDF license).


Getino M.,University of Cantabria | Fernandez-Lopez R.,University of Cantabria | Palencia-Gandara C.,University of Cantabria | Campos-Gomez J.,University of Cantabria | And 5 more authors.
PLoS ONE | Year: 2016

Bacterial conjugation is the main mechanism for the dissemination of multiple antibiotic resistance in human pathogens. This dissemination could be controlled by molecules that interfere with the conjugation process. A search for conjugation inhibitors among a collection of 1,632 natural compounds, identified tanzawaic acids A and B as best hits. They specially inhibited IncW and IncFII conjugative systems, including plasmids mobilized by them. Plasmids belonging to IncFI, IncI, IncL/M, IncX and IncH incompatibility groups were targeted to a lesser extent, whereas IncN and IncP plasmids were unaffected. Tanzawaic acids showed reduced toxicity in bacterial, fungal or human cells, when compared to synthetic conjugation inhibitors, opening the possibility of their deployment in complex environments, including natural settings relevant for antibiotic resistance dissemination. © 2016 Getino et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Loutet S.A.,University of Western Ontario | Loutet S.A.,University of British Columbia | El-Halfawy O.M.,University of Western Ontario | El-Halfawy O.M.,Alexandria University | And 7 more authors.
International Journal of Antimicrobial Agents | Year: 2015

Burkholderia cenocepacia and other members of the Burkholderia cepacia complex (BCC) are highly multidrug-resistant bacteria that cause severe pulmonary infections in patients with cystic fibrosis. Ascreen of 2686 compounds derived from marine organisms identified molecules that could synergisewith polymyxin B (PMB) to inhibit the growth of B. cenocepacia. At 1 μg/mL, five compounds syner-gised with PMB and inhibited the growth of B. cenocepacia by ≥70% compared with growth in PMBalone. Follow-up testing revealed that one compound from the screen, the aminocoumarin antibioticnovobiocin, synergised with PMB and colistin against tobramycin-resistant clinical isolates of B. ceno-cepacia and Burkholderia multivorans. In parallel, we show that novobiocin sensitivity is common among BCC species and that these bacteria are even more susceptible to an alternative aminocoumarin, cloro-biocin, which also had an additive effect with PMB against B. cenocepacia. These studies support using aminocoumarin antibiotics to treat BCC infections and show that synergisers can be found to increasethe efficacy of antimicrobial peptides and polymyxins against BCC bacteria. © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.


PubMed | University of Cantabria and Biomar Microbial Technologies
Type: Journal Article | Journal: PloS one | Year: 2016

Bacterial conjugation is the main mechanism for the dissemination of multiple antibiotic resistance in human pathogens. This dissemination could be controlled by molecules that interfere with the conjugation process. A search for conjugation inhibitors among a collection of 1,632 natural compounds, identified tanzawaic acids A and B as best hits. They specially inhibited IncW and IncFII conjugative systems, including plasmids mobilized by them. Plasmids belonging to IncFI, IncI, IncL/M, IncX and IncH incompatibility groups were targeted to a lesser extent, whereas IncN and IncP plasmids were unaffected. Tanzawaic acids showed reduced toxicity in bacterial, fungal or human cells, when compared to synthetic conjugation inhibitors, opening the possibility of their deployment in complex environments, including natural settings relevant for antibiotic resistance dissemination.


News Article | November 7, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Candidiasis ,complete with analysis by stage of development,drug target,mechanism of action (MoA),route of administration (RoA) and molecule type. The report also coversthe descriptive pharmacological action of the therapeutics,its complete research and development history and latest news and press releases. Additionally,the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios,enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Candidiasis - Pipeline Review, H2 2016 addition with 46 market data tables and 15 figures, spread across 151 pages is available at http://www.rnrmarketresearch.com/coronaviridae-infections-pipeline-review-h2-2016-market-report.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases,company/university websites,clinical trial registries,conferences,SEC filings,investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally,various dynamic tracking processes ensure that the most recent developments are captured on a real time basis (clotrimazole + diclofenac sodium), AC-17,amphotericin BAntibody to Target Ece1 for Candidiasis, APX-001, arasertaconazole,BSG-005, candidiasis vaccine,CD-101, Cellullar Immunotherapy for Viral Infections and Fungal Infections, CTIX-1502,DWP-06081,Forazoline A,iCo-010,KSL-W,MH-010, miconazole nitrate, Monoclonal Antibodies for Candidiasis, obliquumol, Occidiofungin, PAC-113, PMX-1408, SLP-0904, Small Molecule for Bacterial Vaginosis and Candidiasis, Synthetic Peptide to Inhibit CBL-B for Candidiasis, Vaccine for Fungal Infections Amplyx Pharmaceuticals, Bakker Medical Srl, Biomar Microbial Technologies, Biosergen AS, Cellceutix Corporation, Cidara Therapeutics, Daewoong Pharmaceutical Co., Dermala Inc, General Biologicals Corporation, Grupo Ferrer Internacional, Hsiri Therapeutics, Matinas BioPharma Holdings, Nanomerics Ltd, Novabiotics Limited, NovaDigm Therapeutics, Onxeo SA, Scynexis, TGV-Laboratories, Inquire before buying http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=688270This is a premium report price at US$2000 for a single user PDF license).

Loading Biomar Microbial Technologies collaborators
Loading Biomar Microbial Technologies collaborators